Exposure-Response Relationship of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis
|
|
- Leo Ferguson
- 5 years ago
- Views:
Transcription
1 al The Journal of Clinical Pharmacology / Vol XX No XX (20XX) 2012 XX X / Levi et JCP Pharmacokinetics and Pharmacodynamics Exposure-Response Relationship of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody, in a Large Population of Patients With Rheumatoid Arthritis The Journal of Clinical Pharmacology 53(2) The Author(s) 2012 DOI: / Micha Levi, PhD 1, Susan Grange, PhD 2, and Nicolas Frey, PharmD 2 Abstract Relationships between tocilizumab exposure and response were evaluated using data from 4 phase III studies. Increased tocilizumab exposure was associated with improvements in Disease Activity Score using 28 joints (DAS28) and American College of Rheumatology (ACR) criteria and with a decrease in inflammation markers. A population pharmacokinetic/pharmacodynamic (PKPD) model was developed to describe data from 2 studies. An indirect-response model with a sigmoid E max (maximal drug effect) inhibitory drug effect on DAS28 production rate adequately described the relationship between tocilizumab concentration and DAS28. Mean minimum serum tocilizumab concentration at steady state was greater than the EC 50 (concentration at which 50% of E max on DAS28 is reached) with the 8-mg/kg dose but not with the 4-mg/kg dose. Simulations within a large rheumatoid arthritis (RA) population showed that DAS remission rates were 38% for 8 mg/kg and 24% for 4 mg/kg. Tocilizumab was more potent in RA patients with higher baseline interleukin-6 levels, but this effect was not clinically significant. Other covariates (eg, presence of neutralizing antitocilizumab antibodies) did not demonstrate a clinically meaningful effect on tocilizumab DAS28 dose-response relationships. These data support clinical observations that tocilizumab 8 mg/kg is more effective than 4 mg/kg in reducing disease activity. Keywords pharmacodynamics, rheumatology/immunology, clinical pharmacology, immunopharmacology, clinical trials Interleukin-6 (IL-6) is one of the key inflammatory cytokines involved in the development of rheumatoid arthritis (RA). 1,2 Interleukin-6 levels are elevated in the serum and synovial fluid of patients with RA compared with healthy persons. Serum IL-6 levels correlate with disease activity, 3,4 and the presence of IL-6 in joints correlates with chronic synovitis 5 and joint destruction. 6 Tocilizumab is a humanized monoclonal antibody that competitively inhibits IL-6 binding to its soluble and membrane-expressed receptors in a dose-dependent manner, thus blocking multiple IL-6 mediated proinflammatory activities. 7 Tocilizumab was effective and well tolerated in the treatment of RA in phase II and III studies in Japanese 8-10 and European 11 patients. Furthermore, the efficacy and safety of tocilizumab in moderate to severe active RA in various patient populations were confirmed recently in an extensive international phase III clinical program, in which tocilizumab was evaluated in several 24-week clinical trials Actemra (tocilizumab; Roche, Nutley, New Jersey) versus Methotrexate double-blind Investigative Trial In monotherapy (AMBITION) evaluated tocilizumab monotherapy in patients who had not received methotrexate in the 6 months before the study and who had not previously discontinued methotrexate therapy because of toxicity or lack of response. 12 The tocilizumab Pivotal Trial in methotrexate Inadequate responders (OPTION) and Tocilizumab in combination With traditional disease-modifying AntiRheumatic Drug (DMARD) therapy (TOWARD) studies investigated tocilizumab in combination with conventional DMARDs in patients with a previous inadequate response to DMARDs. 13,14 In addition, the Research on Actemra Determining efficacy after Anti-TNF failures (RADIATE) trial investigated tocilizumab in combination with methotrexate in patients with a previous inadequate response to 3 anti tumor necrosis factor (anti-tnf) agents. 15 Secondary objectives of these studies included investigation of the pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity parameters of tocilizumab in these patient populations. Supplementary material for this article is available on the journal s website at 1 Hoffmann La Roche, Inc, Nutley, NJ, USA 2 Hoffmann La Roche AG, Basel, Switzerland Submitted for publication 08-Jul-2011 ; accepted 28-Dec-2011 Corresponding Author: Micha Levi, Pharma Research and Early Development/Translational Research Sciences, Hoffman La Roche, Inc, 340 Kingsland St, Nutley, NJ , USA micha.levi@roche.com
2 152 The Journal of Clinical Pharmacology / Vol 53 No 2 (2013) The PKPD analyses, which use data from clinical trials with dissimilar clinical populations and trial designs, can provide useful integrated information about relationships between drug doses or concentrations and efficacy or safety. 16 In the present evaluation, graphical analyses were used to assess relationships between tocilizumab and key clinical end points and between tocilizumab and biomarkers of inflammation and tocilizumab mechanism of action. A population PKPD model was developed to investigate the relationship between tocilizumab exposure and efficacy, as measured by the Disease Activity Score using a 28-joint count (DAS28). Methods Patient Population Patients with moderate to severe active RA from 4 randomized, double-blind, placebo-controlled, phase III clinical trials of tocilizumab (AMBITION, OPTION, RADIATE, and TOWARD) were included in this analysis In these studies, patients received an intravenous infusion of tocilizumab 4 or 8 mg/kg or placebo (controls) as monotherapy or in combination with methotrexate (10-25 mg/wk) or other DMARDs every 4 weeks for up to 24 weeks. Rescue therapy consisted of tocilizumab 8 mg/kg within 8 weeks in controls in AMBITION, 12 tocilizumab 8 mg/kg from week 16 in OPTION 13 and RADIATE, 15 or an addition or change in DMARD or corticosteroid therapy from week 16 in TOWARD. 14 Data from all studies were pooled for the graphical PKPD analyses. Data from OPTION and TOWARD were used for the development of the PKPD model. PD Biomarkers Levels of markers of inflammation (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], and serum amyloid A [SAA]) and markers of tocilizumab target engagement (serum IL-6 and soluble IL-6 receptor [sil- 6R]) were recorded at screening, baseline, and weeks 2, 4, 6, 8, 12, 14, 16, 20, and 24. Serum IL-6 and sil-6r were measured using Quantikine Human IL-6 and sil- 6R Immunoassays (R&D Systems, Inc, Minneapolis, Minnesota). Clinical End Points 17 DAS28-ESR and American College of Rheumatology (ACR) scores 18 were recorded at baseline and at weeks 2, 4, 8, 12, 16, 20, and 24. For patients who discontinued the study prematurely, efficacy assessments were performed 4 weeks after the last study dose. Graphical Exposure-Response Analysis of PD Biomarkers and Clinical End Points Patients from AMBITION, OPTION, RADIATE, and TOWARD who had available PK parameters when treated with tocilizumab, who had completed the studies, and who did not receive rescue therapy were included in the exposure-biomarker efficacy population. Patients were divided into 3 cumulative tocilizumab area under the curve (AUC) categories: low (AUC < µg/ ml h), medium (AUC 100 and < µg/ml h), and high exposure (AUC µg/ml h). Individual cumulative AUC was calculated using a previously developed population PK model and individual dosing history. 19 Relationships between the main PD biomarkers, efficacy end points, and cumulative tocilizumab AUCs were assessed graphically by comparing the time course of PD parameters for the control group and for groups of low, medium, and high tocilizumab AUCs. Pharmacodynamic parameters analyzed included ACR20/50/70 responses, DAS28, markers of inflammation (CRP, ESR, and SAA concentrations), and markers of tocilizumab target engagement (serum IL-6 and sil-6r concentrations). PKPD Model Development Based on the graphical evaluation of exposure-response relationships, DAS28 was selected as the principal clinical end point for further PKPD modeling because (1) its time course was less variable than that for ACR response, and (2) a continuous variable such as DAS28 is more suitable to nonlinear mixed-effects regression analysis than a dichotomous variable such as ACR response. The PKPD model was developed using patients from OPTION and TOWARD. Patients with available PK parameters and control patients with at least 1 DAS28 value were included in the analysis. Methods and development of the PKPD models are included in supplementary materials. Effect of Neutralizing Antitocilizumab Antibodies. The influence of neutralizing antitocilizumab antibodies (yes or no), a categorical time-varying covariate, on PKPD parameters was investigated using the final model. The importance of change induced by this covariate was assessed graphically by comparing the population- and individual-weighted residuals measured in the presence and absence of neutralizing antitocilizumab antibodies by using a logistic regression. Model Evaluation Visual Predictive Check. The PKPD model was qualified by a visual predictive check (VPC). Parameters were randomly sampled from distributions of interindividual variability. Dependent values (DAS28 scores) were simulated based on sampled PKPD parameters and residual variability. For each individual, covariate values, PK parameters, dosing information, and sampling times were as in the original data set used for model development. One hundred simulated data sets were produced. A 90th percentile prediction interval was created by taking the 5th
3 Levi et al 153 and 95th percentiles of the simulated data at each observation time point. The observed data used for model development were then compared with the prediction interval, and the percentage of observed data points lying outside the interval was computed. To qualify the model, the percentage of data outside the prediction interval had to be ~10%. Posterior Predictive Check. The ability of the model to simulate EUropean League Against Rheumatism (EULAR) improvement criteria 20 and DAS28 remission (DAS28 <2.6) after 24 weeks with placebo or tocilizumab 4 or 8 mg/kg was assessed with a posterior predictive check (PPC). The original data set was simulated 100 times based on sampled parameter values and the same covariate values, dosing information, and individual PK concentration estimates from the original data set. The following criteria of response were calculated at week 24 from the original data set and for each replicate: (1) the proportion of patients with various EULAR improvement criteria (good, moderate, and nonresponders) and (2) the proportion of patients with DAS28 remission. The 5th and 95th percentiles of simulated criteria of response were calculated from all replicates and compared with observed criteria of response. Simulation of DAS28 Response Following 6 Months of Therapy The DAS28 time profiles in 108, 500 patients were simulated after tocilizumab 4 or 8 mg/kg was administered every 4 weeks for 24 weeks. Pharmacodynamic parameters were sampled from distributions of interindividual variability. Dependent values (DAS28 scores) were calculated based on sampled parameter values, residual variability, and the same covariate values in the original data set. Subsequently, proportions of patients with the various EULAR improvement criteria and DAS28 remission were calculated. This process was repeated 100 times, and mean and standard deviation values for the EULAR improvement criteria and DAS28 remission were reported. Results Graphical Analyses: Tocilizumab Exposure Versus Efficacy Parameters and Biomarkers The efficacy-biomarker population comprised 2243 patients who completed the 4 phase III studies. An exposure-response relationship was observed for ACR20/50/70 and DAS28 clinical efficacy end points, with clear differences between the lowest category of tocilizumab exposure (AUC < µg/ml h) and the other categories (Figure 1 ). Across all 4 studies analyzed, levels of markers of inflammation (CRP, ESR, and SAA) decreased with increasing tocilizumab exposure (Figure 2 ). Low levels of these biomarkers (ie, normalization) were sustained between infusions with increasing tocilizumab exposure. Tocilizumab exposure had an effect on other PD biomarkers (IL-6 and sil-6r). IL-6 levels increased initially and then decreased over time, whereas IL-6 fluctuations over time decreased with increasing tocilizumab exposure. Levels of sil-6r increased with higher tocilizumab exposure and did not normalize between consecutive infusions. Similar trends were observed for ACR, DAS28, and markers of inflammation for each clinical trial when analyzed separately (data not shown). PKPD Structural Model The PKPD population for model development comprised 12, 618 DAS28 observations from 1703 patients who had DAS28 data available in the OPTION and TOWARD trials. In general, similar values were observed for all continuous covariates (except duration of RA) across all studies included in the PKPD model (Supplementary Table S1). Approximately 80% of patients were female, with a similar female to male ratio across studies, and patients were predominantly white, again with a similar proportion of races across studies. The distribution of previous RA treatments (DMARDs, methotrexate, and corticosteroids) differed across studies, as would be expected given the different study designs. The structural PKPD model that best described the data was an indirect-response model with a sigmoid inhibition of DAS28 production (K in ) by tocilizumab. The following parameters were estimated: DAS28 first-order rate loss ( ), DAS28 at baseline (BASE), the maximal effect of tocilizumab on K (EC50 in ), the tocilizumab concentration at which 50% of the E max is reached (EC 50 ), the E max mode sigmoidicity coefficient (GAMMA), and a background effect of concomitant therapy with methotrexate or nonmethotrexate DMARDs (DMARD). Additional information on the structural model is provided in the supplementary material. Final Model The final PKPD model estimated population values for the non drug-related parameters BASE and of 6.8 DAS28 units and day 1, respectively. Population mean values for the drug-related parameters EC 50, Emax, and GAMMA were 3.7 µg/ml, 0.73, and 0.64, respectively. The population mean value of background therapy with DMARDs expressed in tocilizumab concentration units was 0.30 µg/ml. The E max effect on K in translates into a maximum decrease in DAS28 scores of 73%, using a typical initial DAS28 baseline score of 6.8. The following 8 covariate relationships were retained in the final model: an inverse relationship between EC 50 and log-transformed IL-6; higher E max in males; higher in blacks and whites combined compared with other
4 154 The Journal of Clinical Pharmacology / Vol 53 No 2 (2013) Figure 1. Effects of tocilizumab exposure on American College of Rheumatology (ACR)20/50/70 responses and Disease Activity Score using 28 joints (DAS28). Abbreviation: AUC, area under the curve. races; positive relationships between BASE and Health Assessment Questionnaire (HAQ), log-transformed IL-6, PAIN, and physician s global score of disease activity (VASP); and an inverse relationship between background DMARD effect in the control group and log-transformed IL-6. Inclusion of these 8 covariates in the final model reduced the objective function by points and decreased interindividual variability of BASE, E max, EC 50, DMARD, and by 42%, 32%, 22%, 15%, and 1.6%, respectively. A correlation term between EC 50 and E max was estimated in the final model. This term did not have a statistically significant effect; however, it enabled successful convergence of the covariance step. The population PD parameters of the final PKPD model are presented in Table 1. The magnitude of covariate effects on the PKPD parameters is summarized in Table 2. The final model goodness-of-fit plots did not reveal any major deficiencies (Supplementary Figure S1). Neutralizing Antitocilizumab Antibodies Eighteen patients had neutralizing antitocilizumab antibodies, and of these patients, 14 had PK samples available for analysis. In an analysis of plots of weighted residuals and individual-weighted residuals versus time, no obvious differences between patients with and without neutralizing antitocilizumab antibodies were observed (data not shown). Model Validation The internal validation using VPCs and PPCs demonstrated good agreement between observed data and model predictions. For VPCs, the proportions of observations above the 95th percentile and below the 5th percentile were 5.9% and 5.8% for the control group, 10.0% and 3.2% for the tocilizumab 4-mg/kg group, and 10.0% and 5.4% for the tocilizumab 8-mg/kg group (Supplementary Figure S2). The PPCs revealed that most of the observed response criteria for EULAR responses and DAS28 remission were within the 90% simulated interval ( Figure 3 ). Tocilizumab 4 mg/kg Versus 8 mg/kg (Model-Based Simulation) The model-based simulation of DAS28 scores after 6 months of tocilizumab 4 mg/kg versus 8 mg/kg in the same large RA population predicted that the mean fraction of patients in DAS28 remission would be 24% (4 mg/kg) versus 38% (8 mg/kg). Mean proportions of
5 Levi et al 155 Figure 2. Effects of tocilizumab exposure on C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and serum amyloid A (SAA) concentrations. Thin gray lines represent individual CRP, ESR, and SAA profiles. The smooth black line represents the median. patients with a EULAR good response would be 32% versus 48%. Corresponding proportions of patients with a moderate EULAR response would be 45% versus 38%, and proportions with no EULAR response would be 22% versus 13%. Simulations were undertaken to illustrate the clinical impact on DAS28 time course of the inverse relationships between baseline IL-6 level and EC 50 and baseline IL-6 level and DMARD background therapy. Predictions were performed for tocilizumab 8 mg/kg, for the effect of IL-6 on EC 50, and for standard-of-care treatment (ie, DMARD) for the effect of IL-6 on DMARD background therapy. To predict a covariate effect at the population level, PKPD parameters were fixed to population values, between-patient variability was set to zero, patients were assumed to have the same tocilizumab exposure (generated by population PK parameters) for the 8-mg/ kg dose, and patients were assumed to have the same set of covariate values expected for baseline IL-6. Figure 4 illustrates the impact of baseline IL-6 on median DAS28 time course by categories of baseline IL-6 level (low, medium, and high). The observed difference between
6 156 The Journal of Clinical Pharmacology / Vol 53 No 2 (2013) Table 1. Model Parameters of Final Population PKPD Model Parameter Unit Estimate RSE, % Fixed effects EC 50 μg/ml E max Day GAMMA Baseline DAS DMARD effect expressed μg/ml as TCZ serum concentrations Covariate effects Effect of log IL-6 on EC Effect of SEX on E max Effect of RACE on Effect of HAQ on BASE Effect of log IL-6 on BASE Effect of PAIN on BASE Effect of VASP on BASE Effect of log IL-6 on DMARD effect Random effects IIV EC 50 CV% a E max CV% a CV% a Baseline CV% a DMARD effect CV% a Correlation EC 50 -E max a Error model Additive DAS Abbreviations: BASE, baseline DAS28; CV, coefficient of variation; DAS28, Disease Activity Score using 28 joints; DMARD, disease-modifying antirheumatic drug; EC 50, concentration at which 50% of E max is reached; E max, maximum tocilizumab effect on ; GAMMA, sigmoidicity coefficient; HAQ, Health Assessment Questionnaire; IIV, interindividual variability; IL-6, interleukin 6;, first-order loss rate of DAS28; PAIN, global pain score; PKPD, pharmacokinetic/pharmacodynamic; RSE, relative standard error of estimate; TCZ, tocilizumab; VASP, physician s global score of disease activity. a RSE of variance. the 2 extreme categories of baseline IL-6 was around the known measurement error of DAS28 (0.60 DAS28 units). Discussion Increasing tocilizumab exposure decreased DAS28 scores, increased ACR responses, and decreased serum concentrations of inflammatory biomarkers (CRP, ESR, and SAA). At exposure levels corresponding to the highest dose of tocilizumab (8 mg/kg), a more sustained suppression of inflammatory biomarkers could be observed over a dosing interval compared with the observed fluctuations in exposure levels corresponding to lower dose tocilizumab (4 mg/kg). These results are consistent with those from individual clinical trials that evaluated both tocilizumab regimens. In OPTION 13 and RADIATE, 15 tocilizumab 8 mg/kg had greater effects on clinical end points (ACR responses and DAS28 remission) and inflammatory biomarkers than did tocilizumab 4 mg/kg. A clear relationship was also evident between serum tocilizumab concentration and biomarkers of tocilizumab target engagement (IL-6 and sil-6r). The observed increase in sil-6r level with increasing tocilizumab concentration is consistent with data in the literature 21 and reflects tocilizumab binding to sil-6r. The sil-6r bioanalytical assay measures free sil-6r, tocilizumab/sil- 6R complexes, and IL-6/sIL-6R complexes. The increase in sil-6r in serum after tocilizumab administration suggests that tocilizumab/sil-6r complexes clear slowly. The observed initial increase in IL-6 level after the first tocilizumab infusion is most likely because IL-6 is normally cleared via membrane-expressed IL-6R (mil-6r), and tocilizumab inhibits this process. The subsequent decrease in IL-6 after the next tocilizumab dose probably reflects reduced IL-6 production because RA disease activity is controlled by tocilizumab. A delay was noted between increased serum tocilizumab concentration and reduced DAS28 score. This indirect relationship was described successfully using an indirect-response model with inhibition of the DAS28 production rate K in. The typical serum tocilizumab concentration at which 50% of E max was reached (EC 50 ) was estimated to be 3.7 µg/ml and was associated with high interindividual variability of 170%. The maximum effect of tocilizumab on DAS28 production (E max ) was estimated to be 73%; using a typical initial DAS28 baseline of 6.8, this corresponds to a maximum reduction of 5 units. The effect of DMARD background therapy in the control group (expressed in tocilizumab concentration units) was equivalent to constant exposure to a serum tocilizumab concentration of 0.30 µg/ml, which translates to a 12% reduction in DAS28 at steady state (ie, a decrease of 0.80 DAS28 units from a typical baseline of 6.8). This effect represents only a small fraction of the total effect observed (for the 2 tocilizumab doses) on background DMARD therapy. The standard deviation of the residual error was estimated to be 0.68 DAS28 units. This value agrees with the known measurement error of DAS28 (0.60 DAS28 units). 20 The relationship between serum tocilizumab concentration and inhibition of K in is displayed in Supplementary Figure S3. After administration of tocilizumab 8 mg/kg, the mean minimum serum concentration at steady state was higher than the EC 50. In contrast, after tocilizumab 4 mg/kg, the mean minimum serum concentration at steady state was less than the EC 50. Baseline DAS28 scores increased with increasing baseline HAQ score, VASP, PAIN, and serum IL-6 concentration. Such positive correlations were expected because these covariates are markers of RA disease activity. The
7 Levi et al 157 Table 2. Covariates With a Statistically Significant Effect in the Final PKPD Model Statistically Significant Effect Relationship Covariate Range (min, max) Percent Change of PKPD Parameters From Typical Value (min, max) Log IL-6 on EC 50 EC 50 = 3.7 *(log(il-6* 1000)/9.9) , , +415 SEX on E max E max = 0.72 * 1.1: male E max = 0.72 * 1.0: Female/male 0/+11 female RACE on = * 1.0: black and white Black and white/asian and others 0/ 25 = * 0.75: Asian and others HAQ on BASE BASE = 6.8 *(HAQ/1.6) , , +2.6 Log IL-6 on BASE BASE = 6.8 *(log(il-6* 1000)/9.9) , , +4.4 PAIN on BASE BASE = 6.8 *(PAIN/60) , , +3.2 VASP on BASE BASE = 6.8 *(VASP/65) , , +5.8 Log IL-6 on DMARD effect DMARD effect = 0.30 *(log (IL-6* 1000)/9.9) , , Abbreviations: BASE, baseline DAS28; DMARD, disease-modifying antirheumatic drug; EC 50, concentration at which 50% of E max is reached; E max, maximum tocilizumab effect on ; HAQ, Health Assessment Questionnaire; IL-6, interleukin 6;, first-order loss rate of DAS28; PAIN, global pain score; PKPD, pharmacokinetic/pharmacodynamic; VASP, physician s global score of disease activity. Figure 3. Posterior predictive check: incidence of EUropean League Against Rheumatism (EULAR) categories and Disease Activity Score using 28 joints (DAS28) remission at week 24. Histograms represent the predicted distribution of the proportion of patients with a EULAR response and DAS28 remission at week 24 (from 100 simulated studies). Dashed vertical lines represent the 5th and 95th percentiles of the simulated criteria of response. The solid vertical line represents the observed criteria of response calculated from the original data set. As seen in the figure, most of the observed responses are within the 90% simulated interval.
8 158 The Journal of Clinical Pharmacology / Vol 53 No 2 (2013) Figure 4. Median Disease Activity score using 28 joints (DAS28) time course (per category of baseline interleukin 6 [IL-6] level) in terms of the relationship between baseline IL-6 level and tocilizumab concentration at which 50% of the E max is reached. observed difference between the 2 extreme categories of baseline IL-6 (low vs high; Figure 4 ) was around the known measurement error of DAS28 (0.60 DAS28 units); this effect therefore was considered to have minor clinical impact. The clinical impact of the relationship between baseline IL-6 level and DMARD background therapy on DAS28 time course also was found to be minor (data not shown). The tocilizumab EC 50 value was lower in patients with high IL-6 levels at baseline. This infers that tocilizumab is more potent in RA patients with high IL-6 levels, which may result from either marked overproduction of IL-6 or lower expression of mil-6r and thus slower clearance of IL-6. However, this effect has a minor clinical impact because the predicted difference in DAS28 between the patients with high or low baseline IL-6 was around the known measurement error of DAS28 (0.6 DAS28 units). Increased baseline IL-6 levels also were found to decrease the effect of background DMARD therapy in the control group. This relationship very likely is an artifact of the way the DMARD effect was accounted for in the PKPD model. The DMARD effect was expressed in serum tocilizumab concentration units and therefore was dependent on the population value for tocilizumab EC 50. The inverse relationship between baseline IL-6 and the DMARD effect possibly is a correction of the inverse relationship between baseline IL-6 and EC 50. The tocilizumab E max value was 11% higher in males than in females. For a typical initial DAS28 baseline of 6.8, this corresponds to a maximum reduction of 5.0 units in males and 4.6 units in females. It is unlikely that the model-based covariate analysis was gender biased because males and females were similarly represented in the data set. This difference is lower than the known measurement error of DAS28 20 and therefore was considered to have no clinical impact. The presence of neutralizing antitocilizumab antibodies did not affect the PKPD model outcomes. The DAS28 population PKPD model was used to compare the effects of tocilizumab 4 mg/kg versus 8 mg/kg on DAS28 scores during 6 months of treatment. Simulations of EULAR response criteria and DAS28 remission rates were performed in the same virtual RA population, composed of more than patients. The simulations assumed full compliance to assigned treatment and no patients dropping out of the study. Response rates in the simulations were higher than observed values because simulated (rather than actual) observed dosing histories were used. Consequently, the predicted effect is larger than the observed effect in the clinical studies. Nevertheless, the simulations are useful to compare the effect of tocilizumab 4 mg/kg versus 8 mg/kg and to capture our best understanding of the inter- and intrasubject variability. Model predictions clearly showed the superiority of tocilizumab 8 mg/kg over 4 mg/kg, especially regarding a greater rate of DAS28 remission (38% vs 24%) and a greater percentage of patients with a good EULAR response (48% vs 32%). In summary, this exposure-response analysis, by using either graphics or a population-modeling approach, supports the observation that tocilizumab 8 mg/kg is more effective than 4 mg/kg. The higher tocilizumab dose is associated with greater tocilizumab exposure, and such increased exposure is associated with greater improvement in DAS28 scores. No covariate had a clinical impact on the effect of tocilizumab on DAS28. Declaration of Conflicting Interests Support for third-party writing assistance for this manuscript was provided by F. Hoffmann La Roche Ltd. All authors are employees of F. Hoffmann La Roche Ltd. Funding This study was funded by F. Hoffmann La Roche Ltd. References 1. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7: Lipsky PE. Interleukin-6 and rheumatic diseases. Arthritis Res Ther. 2006;8(suppl):S4. 3. Madhok R, Crilly A, Watson J, Capell HA. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis. 1993;52: Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol. 1992;19: Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13: Kotake S, Sato K, Kim KJ, et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res. 1996;11: Mihara M, Kasutani K, Okazaki M, et al. Tocilizumab inhibits signal transduction mediated by both mil-6r and sil-6r, but not by
9 Levi et al 159 the receptors of other members of IL-6 cytokine family. Int Immunopharmacol. 2005;5: Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19: Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an antiinterleukin-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis. 2008;68: Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66: Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54: Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69: Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008;371: Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination with Traditional Disease-Modifying Antirheumatic Drug Therapy Study. Arthritis Rheum. 2008;58: Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry: Population Pharmacokinetics. Drugs/Guidancecomplianceregulatoryinformation/Guidances/ Ucm pdf. Accessed November 21, Prevoo MLL, van t Hof H, Kuper H, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum. 1995:38: Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993:36: Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50: van Gestel AM, Prevoo MLL, van t Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism criteria. Arthritis Rheum. 1996;39: Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-il-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112:
New Evidence reports on presentations given at EULAR Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate
New Evidence reports on presentations given at EULAR 2009 Safety and Efficacy of Tocilizumab as Monotherapy and in Combination with Methotrexate Report on EULAR 2009 presentations Tocilizumab inhibits
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Tocilizumab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Tocilizumab monotherapy is superior to adalimumab monotherapy
More informationEfficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2010 Efficacy and Safety of Tocilizumab in the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2010 presentations
More informationNew Evidence reports on presentations given at EULAR Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
New Evidence reports on presentations given at EULAR 2011 Tocilizumab for the Treatment of Rheumatoid Arthritis and Juvenile Idiopathic Arthritis Report on EULAR 2011 presentations Benefit of continuing
More informationMETHODS In the context of an indirect comparison metaanalysis between tocilizumab and other biological
c Additional data are published online only at http://ard.bmj. com/content/vol69/issue1 Correspondence to: Professor M Boers, Department of Epidemiology and Biostatistics, VU University Medical Centre,
More informationN Nishimoto, 1 N Miyasaka, 2 K Yamamoto, 3 S Kawai, 4 T Takeuchi, 5 J Azuma 1. Extended report
1 Osaka University, Osaka, Japan; 2 Tokyo Medical and Dental University, Tokyo, Japan; 3 University of Tokyo, Tokyo, Japan; 4 Toho University Omori Medical Center, Tokyo, Japan; 5 Saitama Medical Center/
More informationIntroduction ORIGINAL ARTICLE
Mod Rheumatol (2007) 17:28 32 Japan College of Rheumatology 2007 DOI 10.1007/s10165-006-0532-0 ORIGINAL ARTICLE Hisashi Yamanaka Yoshiya Tanaka Naoya Sekiguchi Eisuke Inoue Kazuyoshi Saito Hideto Kameda
More informationClinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis
For reprint orders, please contact reprints@expert-reviews.com Clinical pharmacology of tocilizumab for the treatment of systemic juvenile idiopathic arthritis Expert Rev. Clin. Pharmacol. 6(2), 123 137
More informationOrencia (abatacept) for Rheumatoid Arthritis. Media backgrounder
Orencia (abatacept) for Rheumatoid Arthritis Media backgrounder What is Orencia (abatacept)? Orencia (abatacept) is the first biologic agent to be available in both an intravenous (IV) and a self-injectable,
More informationPharmacy Medical Necessity Guidelines: Actemra (tocilizumab)
Pharmacy Medical Necessity Guidelines: Effective: July 11, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review SQ: RXUM/ RX / Pharmacy (RX) or Medical
More informationThe Journal of Rheumatology Volume 41, no. 1
The Journal of Volume 41, no. 1 Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan Takao Koike, Masayoshi Harigai, Shigeko Inokuma,
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationM. Schoels 1, F. Alasti 2, J. S. Smolen 1,2 and D. Aletaha 2*
Schoels et al. Arthritis Research & Therapy (2017) 19:155 DOI 10.1186/s13075-017-1346-5 RESEARCH ARTICLE Evaluation of newly proposed remission cut-points for disease activity score in 28 joints (DAS28)
More informationAbatacept (Orencia) for active rheumatoid arthritis. August 2009
Abatacept (Orencia) for active rheumatoid arthritis August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Comparative Effectiveness Studies of Biologics Learning Objectives Understand the motivation for comparative effectiveness research
More informationComparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity
7 Comparison of long-term clinical outcome with etanercept and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity Charlotte Krieckaert* Anna Jamnitski* Mike Nurmohamed Piet Kostense
More informationNew Evidence reports on presentations given at ACR Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab
New Evidence reports on presentations given at ACR 2009 Improving Radiographic, Clinical, and Patient-Reported Outcomes with Rituximab From ACR 2009: Rituximab Rituximab in combination with methotrexate
More informationReceived: 27 May 2003 Revisions requested: 26 Jun 2003 Revisions received: 14 Aug 2003 Accepted: 19 Aug 2003 Published: 1 Oct 2003
Research article Etanercept versus etanercept plus methotrexate: a registrybased study suggesting that the combination is clinically more efficacious Ronald F van Vollenhoven 1, Sofia Ernestam 2, Anders
More informationGolimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis
Clinical Medicine Reviews in Therapeutics Review Golimumab: In Combination with Methotrexate as Once Monthly Treatment for Moderate to Severe Rheumatoid Arthritis Lauren Keyser McCluggage 1 and Kelly Michelle
More informationGolimumab: a novel anti-tumor necrosis factor
Golimumab: a novel anti-tumor necrosis factor Rossini M, De Vita S, Ferri C, et al. Biol Ther. 2013. This slide deck represents the opinions of the authors, and not necessarily the opinions of the publisher
More informationSYNOPSIS. The study results and synopsis are supplied for informational purposes only.
SYNOPSIS INN : LEFLUNOMIDE Study number : HMR486/1037 et HMR486/3503 Study title : Population pharmacokinetics of A77 1726 (M1) after oral administration of leflunomide in pediatric subjects with polyarticular
More informationSynopsis (C0524T12 GO LIVE)
Protocol: EudraCT No.: 2005-003232-21 Title of the study: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFα Monoclonal Antibody, Administered Intravenously,
More informationBringing the clinical experience with anakinra to the patient
Rheumatology 2003;42(Suppl. 2):ii36 ii40 doi:10.1093/rheumatology/keg331, available online at www.rheumatology.oupjournals.org Bringing the clinical experience with anakinra to the patient S. B. Cohen
More informationOptimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
RHEUMATOLOGY Rheumatology 2012;51:v12 v21 doi:10.1093/rheumatology/kes111 Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs Karel
More informationSynopsis (C0743T10) CNTO 1275 Module 5.3 C0743T10. Associated with Module 5.3 of the Dossier
Module 5.3 Protocol: EudraCT No.: 2005-003525-92 Title of the study: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of, a Fully Human Anti-IL-12 Monoclonal Antibody, Administered
More informationof 0.20) and Health assessment questionnaire disability index (HAQ-DI) (r partial
IL-6 receptor inhibition modulates type III collagen and C-reactive protein degradation in rheumatoid arthritis patients with an inadequate response to anti-tumour necrosis factor therapy: analysis of
More informationClinical Policy: Tocilizumab (Actemra) Reference Number: ERX.SPMN.44
Clinical Policy: (Actemra) Reference Number: ERX.SPMN.44 Effective Date: 10/16 Last Review Date: 09/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationG Wells, 1 J-C Becker, 2 J Teng, 2 M Dougados, 3 M Schiff, 4 J Smolen, 5 D Aletaha, 6 P L C M van Riel 7. Extended report
1 Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Canada; 2 Bristol-Myers Squibb, Princeton, New Jersey, USA; 3 Paris-Descartes University, Medicine Faculty and UPRES-EA
More informationAlthough this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as
Although this presentation includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice. Forward-Looking
More informationCriteria Inclusion criteria Exclusion criteria. despite treatment with csdmards, NSAIDs, and/or previous anti-tnf therapy and/or
Supplementary Material Table S1 Eligibility criteria (PICOS) for the SLR Criteria Inclusion criteria Exclusion criteria Population Adults (aged 18 years) with active PsA despite treatment with csdmards,
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationTocilizumab for the treatment of rheumatoid arthritis
Therapy in Practice Tocilizumab for the treatment of rheumatoid arthritis Javier Rueda-Gotor*, Miguel A González-Gay & Ricardo Blanco Practice Points IL is a cytokine with a very important role in the
More informationRheumatoid arthritis 2010: Treatment and monitoring
October 12, 2010 By Yusuf Yazici, MD [1] The significant changes in the way rheumatoid arthritis has been managed include earlier, more aggressive treatment with combination therapy. Significant changes
More information1 Executive summary. Background
1 Executive summary Background Rheumatoid Arthritis (RA) is the most common inflammatory polyarthropathy in the UK affecting between.5% and 1% of the population. The mainstay of RA treatment interventions
More informationRoActemra (tocilizumab) NICE STA Submission ACHIEVING CLINICAL EXCELLENCE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS
RoActemra (tocilizumab) NICE STA Submission ACHIEVING CLINICAL EXCELLENCE IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS Roche Submission to the National Institute for Health and Clinical
More informationPrincipal Investigator. General Information. Conflict of Interest. Certification Published on The YODA Project (
Principal Investigator First Name: Liana Last Name: Fraenkel Degree: MD, MPH Primary Affiliation: Yale University School of Medicine E-mail: christine.ramsey@gmail.com Phone number: 610-613-6745 Address:
More information1.0 Abstract. Title. Keywords. Rationale and Background
1.0 Abstract Title A Prospective, Multi-Center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate its Effect on Synovitis Using Ultrasonography in an Egyptian Population Keywords Synovitis
More informationTime to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect
Adjustment of k e0 to Reflect True Time Course of Drug Effect by Using Observed Time to Lowest BIS after an Intravenous Bolus and an Adaptation of the Time-topeak-effect Algorithm Reported by Shafer and
More informationCorrespondence should be addressed to Martin J. Bergman;
Autoimmune Diseases Volume 2013, Article ID 367190, 7 pages http://dx.doi.org/10.1155/2013/367190 Research Article Composite Indices Using 3 or 4 Components of the Core Data Set Have Similar Predictive
More informationThis is a repository copy of Targeting interleukin-6 in rheumatoid arthritis.
This is a repository copy of Targeting interleukin-6 in rheumatoid arthritis. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/85075/ Version: Accepted Version Article: Md
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationOptimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
Mian et al. Arthritis Research & Therapy (2016) 18:142 DOI 10.1186/s13075-016-1028-8 RESEARCH ARTICLE Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction
More informationTreat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK
Treat - to - Target Pathway Commissioning Chronic and Complex Care MIDLANDS RHEUMATOLOGY & MUSCULOSKELETAL (MSK) COMMISSIONING NETWORK Dr Bruce Kirkham Consultant Rheumatologist Guy s & St Thomas NHS Foundation
More informationScottish Medicines Consortium
Scottish Medicines Consortium abatacept, 250mg powder for concentrate for solution (Orencia ) No. (400/07) Bristol Myers Squibb Pharmaceuticals Ltd 10 August 2007 The Scottish Medicines Consortium has
More informationPage: 17 December 2012 (Study M13-692) 22 October 2013 (Study M13-692)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: D2E7 Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title of Studies:
More informationKeywords Rheumatoid arthritis Infliximab Total van der Heijde Sharp score Joint destruction. Introduction
Mod Rheumatol (2008) 18:447 454 DOI 10.1007/s10165-008-0077-5 ORIGINAL ARTICLE Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationRelative effect (95% CI) RR LOW 2,3 due to indirectness, imprecision. RR 1.45 (0.43 to 4.84) due to indirectness, imprecision. (0.18 to 20.
Appendix: Evidence Reports Question In patients with early RA with moderate or high disease activity, who are DMARD-naive, what is the impact of combination double DMARD therapy vs. mono-dmard therapy
More informationThe Rate of Decrease in the Disease Activity of Rheumatoid Arthritis during Treatment with Adalimumab Depends on the Dose of Methotrexate
ORIGINAL ARTICLE The Rate of Decrease in the Disease Activity of Rheumatoid Arthritis during Treatment with Adalimumab Depends on the Dose of Methotrexate Koei Oh 1,2, Satoshi Ito 1, Megumi Unno 1,3, Daisuke
More informationExtended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;
1 Denver Arthritis Clinic, Denver, Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; 3 Health Research of Oklahoma, Oklahoma City, Oklahoma, USA; 4 Arthritis &
More informationThe Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines and Disease Activity in Rheumatoid Arthritis Patients
Original Article DOI 10.3349/ymj.2011.52.1.113 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 52(1):113-120, 2011 The Correlation between Increased Serum Concentrations of Interleukin-6 Family Cytokines
More informationA. Kopchev, S.Monov, D. Kyurkchiev, I.Ivanova, T. Georgiev (UMHAT St. Ivan Rilski, Medical University - Sofia, Bulgaria)
International Journal of Pharmaceutical Science Invention ISSN (Online): 2319 6718, ISSN (Print): 2319 670X Volume 6 Issue 7 July 2017 PP. 08-12 Vascular endothelial growth factor (VEGF), cartilage oligomeric
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationPRODUCT INFORMATION HUMIRA
NAME OF THE MEDICINE Adalimumab (rch) DESCRIPTION PRODUCT INFORMATION HUMIRA (adalimumab) is a recombinant human immunoglobulin (IgG1) monoclonal antibody containing only human peptide sequences. was created
More informationACTEMRA (tocilizumab)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Actemra is an agent in the class of drugs known as biologic disease modifiers. It is used to treat adult onset rheumatoid (RA) arthritis, polyarticular
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23689
More informationACTEMRA (tocilizumab)
ACTEMRA (tocilizumab) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationExtended report. Colorado, USA; 2 Pontificial Catholic University, School of Medicine, Porto Alegre, Brazil; Oklahoma City, Oklahoma, USA;
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate
More informationEMA EFPIA workshop Break-out session no. 2
EMA EFPIA workshop Break-out session no. 2 Case Study Title: Improvement of clinical benefit for a sub-group of pediatric systemic Juvenile Idiopathic Arthritis (sjia)) patients utilizing model-based dose
More informationTechnology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480
Tofacitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 11 October 2017 nice.org.uk/guidance/ta480 NICE 2018. All rights reserved. Subject to Notice of rights
More informationORIGINAL ARTICLE R. F. VAN VOLLENHOVEN, 1 D. FELSON, 2 V. STRAND, 3 M. E. WEINBLATT, 4 K. LUIJTENS, 5 AND E. C. KEYSTONE 6 INTRODUCTION
Arthritis Care & Research Vol. 63, No. 1, January 2011, pp 128 134 DOI 10.1002/acr.20331 2011, American College of Rheumatology ORIGINAL ARTICLE American College of Rheumatology Hybrid Analysis of Certolizumab
More informationA Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases
Rheumatol Ther (2018) 5:21 42 https://doi.org/10.1007/s40744-018-0102-x REVIEW A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases Andrea Rubbert-Roth. Daniel E. Furst.
More informationKey findings towards optimising adalimumab treatment: the concentration-effect curve
4 Key findings towards optimising adalimumab treatment: the concentration-effect curve Mieke Pouw* Charlotte Krieckaert* Mike Nurmohamed Theo Rispens Desiree van der Kleij Lucien Aarden Gertjan Wolbink
More informationGuideline on clinical investigation of medicinal products for the treatment of rheumatoid arthritis
14 December 2017 CPMP/EWP/556/95 Rev. 2 Committee for Medicinal Products for Human Use (CHMP) Guideline on clinical investigation of medicinal products for the treatment of Draft Agreed by Rheumatology-Immunology
More informationAppendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview. Trial duration in months
Appendix 2 (as provided by the authors): List of studies in the reviews included for analyses in the overview Study Name Year Reference ABATACEPT (n=7) Moreland 2002 Moreland LW, Alten R, Van den Bosch
More informationAuthor(s) Syuji; Tanaka, Yoshiya; Ito, Kyoko; Yamanaka, Hisash. review and can also be viewed on the journal's websi. Instructions for use
Title Postmarketing surveillance of tocilizumab for rheuma Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko; Author(s) Syuji; Tanaka, Yoshiya; Ito, Kyoko; Yamanaka, Hisash CitationAnnals of the Rheumatic
More informationEfficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis
New Evidence reports on presentations given at ACR/ARHP 2010 Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis Report on ACR/ARHP 2010 presentations
More informationABSTRACT Background. Methods. Results. Conclusions
Chapter 3 Clinical response to adalimumab: the relationship with antiadalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis G.M. Bartelds C.A. Wijbrandts M.T. Nurmohamed S. Stapel
More informationRecommendations for RA management: what has changed?
The 2016 Update of the EULAR Recommendations for RA management: what has changed? Baltics Rheumatology Conference Vilnius, September 21-22 Prof. Diego Kyburz University Hospital of Basel Switzerland Multiple
More informationWhat does it mean for Pharmacists?
18th Congress of the European Association of Hospital Pharmacists (EAHP) Paris, 14 March 2013 What does it mean for Pharmacists? Value-based Decision Making in Rheumatic Disease Pr. REES France 28, Rue
More informationCase Study in Placebo Modeling and Its Effect on Drug Development
Case Study in Placebo Modeling and Its Effect on Drug Development Modeling and Simulation Strategy for Phase 3 Dose Selection of Dasotraline in Patients With Attention-Deficit/Hyperactivity Disorder Julie
More informationTechnology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor Technology appraisal guidance Published: 25 August 2010 nice.org.uk/guidance/ta195
More informationTitle: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations
1 SUPPLEMENTARY MATERIALS 2 3 4 5 6 7 8 Title: Defining the optimal dose of rifapentine for pulmonary tuberculosis: Exposure-response relations from two Phase 2 clinical trials Authors: Radojka M. Savic,
More informationMaasa Hama Takeaki Uehara Kaoru Takase Atsushi Ihata Atsuhisa Ueda Mitsuhiro Takeno Kazuya Shizukuishi Ukihide Tateishi Yoshiaki Ishigatsubo
Rheumatol Int (2012) 32:1327 1333 DOI 10.1007/s00296-011-1802-5 ORIGINAL ARTICLE Power Doppler ultrasonography is useful for assessing disease activity and predicting joint destruction in rheumatoid arthritis
More informationTreating Rheumatologic Disease in Arizona: Good News, Bad News
Treating Rheumatologic Disease in Arizona: Good News, Bad News Jeffrey R. Lisse, M.D. Ethel P. McChesney Bilby Professor of Medicine Chief, Section of Rheumatology University of Arizona School of Medicine
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationThe BeSt way of withdrawing biologic agents
The BeSt way of withdrawing biologic agents C.F. Allaart 1, W.F. Lems 2, T.W.J. Huizinga 1 1 Department of Rheumatology, Leiden University Medical Center, Leiden; 2 Department of Rheumatology, Free University
More informationSupplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General
Supplemental Table 1. Key Inclusion Criteria Inclusion Criterion OPTIMA PREMIER 18 years old with RA (per 1987 revised American College of General Rheumatology classification criteria) 34 ; erythrocyte
More informationCitation for final published version:
This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: http://orca.cf.ac.uk/97756/ This is the author s version of a work that was submitted to / accepted
More informationSafety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis
1. Title: Safety and effectiveness of biologic Disease-Modifying Antirheumatic Drugs in elderly patients with rheumatoid arthritis 2. Background: The population of older individuals with rheumatoid arthritis
More informationTechnology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466
Baricitinib for moderate to severeere rheumatoid arthritis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta466 NICE 2017. All rights reserved. Subject to Notice of rights
More informationPerformance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies
Performance of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients under biological therapies 1. Introduction The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a new instrument
More informationPsA. SIMPONI (golimumab) Rheumatoid arthritis. Psoriatic arthritis. Ankylosing spondylitis EFFICACY EFFICACY EFFICACY. QoL. QoL.
RA Rheumatoid arthritis PsA Psoriatic arthritis AS Ankylosing spondylitis EFFICACY EFFICACY EFFICACY QoL QoL QoL SAFETY SAFETY SAFETY EXPERIENCE EXPERIENCE EXPERIENCE SUMMARY SUMMARY SUMMARY Copyright
More informationCharité - University Hospital, Free University and Humboldt University of Berlin, Berlin, Germany; 2 Sanofi Genzyme, Bridgewater, NJ, USA; 3
Efficacy and Safety of Sarilumab Versus Adalimumab in a Phase 3, Randomized, Double-blind, Monotherapy Study in Patients With Active Rheumatoid Arthritis With Intolerance or Inadequate Response to Methotrexate
More informationThe EULAR OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint
i23 The EULAR OMERACT rheumatoid arthritis MRI reference image atlas: the wrist joint B Ejbjerg, F McQueen, M Lassere, E Haavardsholm, P Conaghan, P O Connor, P Bird, C Peterfy, J Edmonds, M Szkudlarek,
More informationRheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy
Rheumatoid Arthritis: When to Start and when to Stop anti-tnf Therapy [ Cuando iniciar o detener la tx anti-tnf?] Asociacion Costatarricense Medicina Interna August 7, 2015 Arthur Weinstein, MD, FACP,
More informationABSTRACT ORIGINAL RESEARCH. Alan Kivitz. Thomas Wallace. Ewa Olech. Michael Borofsky. Jenny Devenport. Jinglan Pei. Margaret Michalska
Rheumatol Ther (2016) 3:291 304 DOI 10.1007/s40744-016-0043-1 ORIGINAL RESEARCH Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase
More informationIL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis
To cite: Wang J, Platt A, Upmanyu R, et al. IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open 2013;3: e003199. doi:10.1136/ bmjopen-2013-003199
More informationPharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab, a Recombinant Humanized Anti-Interleukin-6 Receptor Antibody
Clinical Medicine: Therapeutics R e v i e w Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Pharmacotherapy Options in Rheumatoid Arthritis: Focus on Tocilizumab,
More informationABSTRACT. DMARD- and biologic-naïve Japanese patients
DOI 10.1007/s40744-017-0059-1 ORIGINAL RESEARCH Adalimumab with Methotrexate in Treatment-Naïve Japanese Patients with Rheumatoid Arthritis at Risk of Progressive Structural Joint Damage: A Postmarketing
More informationReview Article Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
Clinical and Developmental Immunology Volume 2013, Article ID 310628, 16 pages http://dx.doi.org/10.1155/2013/310628 Review Article Efficacy and Safety of Iguratimod for the Treatment of Rheumatoid Arthritis
More informationMeasuring Patient Outcomes:
Measuring Patient Outcomes: Interplay of science, policy and marketing Chapel Hill, November 22, 22 Dr. Claire Bombardier Professor of Medicine, University of Toronto Senior Scientist, Institute for Work
More informationVarun Goel 1, Nathalie H Gosselin 2, Claudia Jomphe 2, Husain Attarwala 1, Xiaoping (Amy) Zhang 1, JF Marier 2, Gabriel Robbie 1
Population Pharmacokinetic (PK) / Pharmacodynamic (PD) Model of Serum Transthyretin (TTR) Following Patisiran Administration in Healthy Volunteers and Patients with Hereditary TTR-Mediated (hattr) Amyloidosis
More informationThis is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors..
This is a repository copy of Treating active rheumatoid arthritis with Janus kinase inhibitors.. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/118272/ Version: Accepted
More informationDivision of Rheumatology, Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland 4
Original papers Efficacy and safety of golimumab as add-on therapy to standard disease-modifying antirheumatic drugs: Results of the GO-MORE study in the Polish population Sławomir Jeka 1,A,B,D F, Bogdan
More informationImmunological Aspect of Ozone in Rheumatic Diseases
Immunological Aspect of Ozone in Rheumatic Diseases Prof. Dr. med. Z. Fahmy Chief Consulting Rheumatologist Augusta Clinic for Rheumatic Diseases And Rehabilitation Bad Kreuznach Germany Rheumatoid arthritis
More informationConcordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent
Concordance with the British Society of Rheumatology (BSR) 2010 recommendations on eligibility criteria for the first biologic agent Michela Frendo, John Paul Caruana Galizia, Andrew A Borg Abstract Aims:
More informationConcise report. Additional supplementary data are published online only. To view these fi les please visit the journal online ( bmj.
Additional supplementary data are published online only. To view these fi les please visit the journal online (http://ard. bmj.com) 1 Department of Rheumatology, University of Colorado School of Medicine,
More information